Bruker
BRKR
$58.84
+1.59%
Bruker Corporation designs and manufactures high-performance scientific instruments and analytical/diagnostic solutions for the life sciences, pharmaceutical, biotechnology, applied, and materials research markets, organized across BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST), with the BSI CALID segment generating the largest share of revenue and the United States representing its biggest geographic market. Bruker occupies a differentiated position as a high-end, premium-priced instrumentation franchise whose magnetic resonance, mass spectrometry, and nano-analysis platforms are deeply embedded in academic, government, and pharma research workflows, giving it a narrow-moat-like competitive identity built on technical leadership, installed-base lock-in, and a large recurring service and consumables stream rather than on scale-driven commodity competition. The current investor narrative is dominated by a sharp debate over earnings quality and margin trajectory: the company swung to a Q2 2026 net loss of $52 million and negative $0.41 diluted EPS despite 5.15% year-over-year revenue growth to $838.5 million, while a dramatic August 4 share-price gap (from $64.31 to $50.30) suggests the market reacted violently to a guidance or order-book disappointment. Bulls point to a 63.8% one-year total return, a 45.9% gross margin, and a forward PE near 24x as evidence that the earnings trough is cyclical and self-inflicted rather than structural, while bears highlight negative trailing EPS, a -0.25% net margin, and a 6.29 short ratio as signs that the premium multiple rests on an unproven recovery.…
BRKR
Bruker
$58.84
Investment Opinion: Should I buy BRKR Today?
We assign a Hold rating on BRKR. The company is a high-quality franchise with a narrow moat, but the recent swing to a net loss and premium valuation on depressed earnings warrant caution. The analyst consensus is Buy with an average target of $63.67, implying 8.2% upside, but the risk/reward is balanced given the wide target range ($50-$80) and the need for a proven earnings recovery. Supporting evidence includes a 63.8% one-year total return, a 45.9% gross margin, and a forward PE of 24.39x based on estimated EPS of $3.50. However, the trailing PS of 2.08x is at the low end of its historical range, suggesting the market is pricing in structural issues. The PEG ratio of 2.62 indicates the stock is not cheap relative to growth. Risks include the potential for further margin compression, weak cash flow, and high short interest. The rating would upgrade to Buy if the company demonstrates a clear earnings inflection, such as positive net income and operating cash flow in the next quarter, or if the stock pulls back to the $50 level. It would downgrade to Sell if revenue growth turns negative or if operating margins fail to recover above 10%. Relative to its history and peers, the stock appears fairly valued to slightly overvalued on current earnings, but undervalued if the recovery materializes.
Sign up to view all
BRKR 12-Month Price Forecast
Bruker presents a balanced risk/reward profile. The company's strong gross margins and installed base provide a foundation, but the recent swing to a net loss and premium valuation multiples on depressed earnings are concerning. The analyst consensus expects a recovery, but the wide target range and high short interest suggest uncertainty. We would upgrade to bullish if the next quarterly report shows a clear earnings inflection and positive free cash flow. Conversely, a downgrade to bearish would be warranted if revenue growth turns negative or if operating margins fail to improve, leading to further multiple compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $63.67 and implied upside of +8.2% versus the current price.
Average Target
$63.67
0 analysts
Implied Upside
+8.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$50 - $80
Analyst target range
Coverage is solid with 12 analysts, and the consensus recommendation is Buy with a recommendation mean of 2.23 (where lower is more bullish). The average target price is $63.67, which implies roughly 8.2% upside from the current $58.84, a modest but positive expected return that leans cautiously bullish rather than conviction Buy. The consensus EPS estimate of $3.50 for the forward period is the linchpin of that target, and the tight estimate range ($3.46 to $3.55) shows analysts broadly agree on the earnings recovery path even as the stock trades below the average target. The target range runs from a low of $50.00 to a high of $80.00, a wide 60% spread that signals genuine disagreement about the durability of the margin recovery. The $80 high target implies multiple expansion and a successful normalization of profitability back toward historical levels, while the $50 low target effectively prices in continued margin compression and a retest of the August gap low. Institutional ratings show a stable-to-constructive tone with no recent downgrades: Leerink Partners reiterated Outperform on September 29, 2026, UBS and Citigroup have stayed Neutral through 2026, and Barclays, JP Morgan, and Guggenheim remain constructive with Overweight/Buy ratings. The pattern of reiterated rather than upgraded ratings suggests analysts are waiting for evidence of an earnings inflection before raising targets, which means the next quarterly print is likely the key catalyst that determines whether the stock converges toward the $63.67 average or drifts back toward the $50 low.
Bulls vs Bears: BRKR Investment Factors
The bull case rests on Bruker's strong brand, high gross margins, and a likely cyclical earnings recovery that analysts expect to materialize by 2027. The bear case highlights the recent swing to a net loss, premium valuation multiples on depressed earnings, and weak cash flow generation. Currently, the bear evidence appears stronger because the company is unprofitable on a trailing basis and the forward estimates require a significant turnaround that has not yet been proven. The most critical tension is whether the Q2 loss was a one-time event or signals structural margin pressure; if margins normalize, the stock could re-rate toward the analyst average target of $63.67, but if losses persist, the downside could test the $50 low target.
Bullish
- Strong 1-year momentum and relative strength: BRKR is up 63.76% over the past year, outperforming SPY by 47.76 percentage points. This sustained outperformance suggests underlying business recovery and positive market sentiment despite recent earnings volatility.
- Attractive price-to-sales valuation: The PS ratio of 2.08x is at the low end of its historical range (5.7x to 18.7x), indicating the market may be overly pessimistic. If margins normalize, the stock could re-rate significantly higher.
- Solid gross margin and recurring revenue: Gross margin remains healthy at 45.9% (49.6% in Q2 2026), reflecting pricing power and a large installed base of high-margin instruments and services. This provides a cushion for future profitability.
- Analyst consensus Buy with upside: 12 analysts rate the stock a Buy (mean 2.23) with an average target of $63.67, implying 8.2% upside from $58.84. The high target of $80 suggests significant recovery potential if earnings inflect.
Bearish
- Recent swing to net loss: Q2 2026 net income was -$52 million (-$0.41 EPS) versus +$7.6 million a year ago, with negative operating and net margins. This raises concerns about cost control and earnings quality.
- Premium valuation on depressed earnings: EV/EBITDA of 29.4x and price-to-cash-flow of 53.3x are well above typical life-science tools peers (high-teens to low-20s EV/EBITDA). The forward PE of 24.39x leaves little margin of safety if recovery stalls.
- Weak cash flow and balance sheet: Trailing free cash flow is only $93.9 million (1.3% FCF yield), and Q2 2026 operating cash flow was -$77.4 million. Debt-to-equity of 0.83 and a current ratio of 1.73 are adequate but not fortress-like.
- High short interest and volatility: Short ratio of 6.29 and beta of 1.223 indicate significant bearish sentiment and above-market volatility. The stock's max drawdown of -39.85% shows the potential for sharp declines.
BRKR Technical Analysis
Bruker is in a broad recovery uptrend that has stalled into a high-level consolidation. The stock is up 63.76% over the past year and 56.53% over six months, yet it trades at $58.84, only about 77% of its 52-week range (low $32.37, high $66.98), meaning it has given back roughly a quarter of its peak-to-trough advance and sits in the upper-middle of its annual band rather than at the highs. That positioning implies the market has already rewarded the recovery but is no longer willing to pay up without confirmation, leaving the stock vulnerable to a retest of the mid-$50s if momentum fades. Recent momentum is mixed and decelerating: the 1-month change is +8.10% and the 6-month change is +56.53%, but the 3-month change is -2.03%, a clear divergence that signals the powerful spring rally has cooled into a sideways churn. Relative strength confirms the split — BRKR beat SPY by 5.98 points over one month and 41.94 points over six months, but lagged by 5.16 points over three months — and the 1.59% up-day on October 9 came on modest volume of 1.47 million shares, suggesting no urgent institutional accumulation. The key levels are the 52-week high at $66.98 as resistance and the 52-week low at $32.37 as the ultimate support, with the August 4 gap zone near $50.30 acting as the more immediate demand shelf. A decisive break above $66.98 would confirm a new leg higher and validate the recovery thesis, while a breakdown below $50 would reopen the gap and likely target the mid-$40s. With a beta of 1.223, the stock is roughly 22% more volatile than the S&P 500, and a max drawdown of -39.85% over the period shows how violently this name can move, so position sizing should assume wider-than-market swings.
Beta
1.22
1.22x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$32-$67
Price range past year
Annual Return
+63.8%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | +8.1% | +1.9% |
| 3m | -2.0% | +3.9% |
| 6m | +56.5% | +12.1% |
| 1y | +63.8% | +19.2% |
| ytd | +22.3% | +14.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Bruker's revenue trajectory is growing but at a decelerating pace. Q2 2026 revenue of $838.5 million rose 5.15% year over year versus $797.4 million in Q2 2025, a slowdown from the prior-year comparison, and the quarterly sequence of $823.4 million (Q1 2026), $977.2 million (Q4 2025), $860.5 million (Q3 2025), and $797.4 million (Q2 2025) shows a business that is seasonal and essentially flat-to-modestly-growing rather than compounding. The product line dominates the mix at $663.7 million versus $174.8 million in product-and-service-other revenue, so overall growth is hostage to instrument capex cycles in pharma and academia; the 5.15% growth rate is respectable for a mature tools company but far below what a 24x forward PE would normally demand. Profitability has deteriorated sharply and is the central problem: Q2 2026 net income was -$52 million (a -6.20% net margin) versus +$7.6 million in Q2 2025, with operating income of -$65.3 million and a -7.79% operating margin, even though gross margin held at 49.61% and gross profit was $416 million. The gap between a healthy 45.9% gross margin and a negative net margin is explained by $481.3 million of operating expenses, including $94.3 million of R&D and $238.9 million of SG&A, plus $148.1 million of other expenses — evidence of cost inflation and possibly one-time charges rather than gross-margin erosion. The balance sheet is serviceable but not fortress-like: debt-to-equity is 0.83, the current ratio is 1.73, and trailing free cash flow is only $93.9 million against a $7.15 billion market cap, a thin 1.3% FCF yield. Q2 2026 operating cash flow was -$77.4 million and free cash flow was -$106.2 million as working capital consumed $196.9 million, while the company repaid $167.7 million of debt and paid $18.5 million of dividends, leaving cash at $189.1 million; ROE is -0.35% and ROA is 3.14%, confirming that returns are currently inadequate relative to the cost of capital and that the dividend is being funded from a position of weakness.
Quarterly Revenue
$838500000.0B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
49.6%
Latest Quarter
Free Cash Flow
$93900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Because trailing net income is negative (EPS of -$0.0012 and a trailing PE of -314.07x), the PE ratio is not meaningful, so the primary metric selected is the price-to-sales ratio of 2.08x, supported by the forward PE of 24.39x as the market's earnings-based anchor. The gap between the meaningless trailing PE and the 24.39x forward PE implies the market expects a sharp earnings recovery, and the PEG ratio of 2.62 suggests that even on those forward estimates the stock is not cheap relative to expected growth. On a peer basis, the 2.08x PS and 3.01x EV/Sales look undemanding for a high-end scientific instruments franchise, but the 29.40x EV/EBITDA and 53.33x price-to-cash-flow ratios reveal that the headline sales multiple is flattered by depressed profitability; versus a typical life-science tools peer group trading in the high-teens to low-20s EV/EBITDA, Bruker's 29.4x represents a meaningful premium that is hard to justify with a -0.25% net margin and 6.87% operating margin. The 2.91x price-to-book is also above where the stock traded through much of 2025, when PB dipped to 2.03x in Q3 2025, indicating the market has already re-rated the equity ahead of the earnings recovery. Historically, Bruker's PS ratio has ranged from roughly 5.7x in Q3 2025 to 18.7x in Q1 2024, so the current 2.08x sits at the very bottom of its own multi-year band — a classic value signal if margins normalize, but also a warning that the market is pricing in structural deterioration rather than a temporary trough. The forward PE of 24.39x against estimated EPS of $3.50 implies investors are paying a full multiple for earnings that have not yet materialized, leaving little margin of safety if the recovery slips.
PE
-314.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated. Bruker swung to a Q2 2026 net loss of $52 million with negative operating and net margins, despite a 49.6% gross margin. Operating expenses of $481.3 million, including $94.3 million in R&D and $238.9 million in SG&A, are consuming gross profits, and trailing free cash flow is only $93.9 million against a $7.15 billion market cap, yielding a thin 1.3% FCF yield. The company also carries $0.83 debt-to-equity and a current ratio of 1.73, leaving limited cushion if earnings do not recover. Market and competitive risks include valuation compression if the earnings recovery disappoints. The stock trades at 29.4x EV/EBITDA and 53.3x price-to-cash-flow, well above peers, and a forward PE of 24.39x leaves little room for error. With a beta of 1.223, BRKR is 22% more volatile than the S&P 500, and the 6.29 short ratio indicates significant bearish positioning. Additionally, the company operates in cyclical research and pharma capex markets, which are sensitive to funding cycles and macroeconomic conditions. The worst-case scenario would be a continued deterioration in margins and order bookings, leading to further earnings misses and analyst downgrades. In that scenario, the stock could retest its 52-week low of $32.37, representing a 45% decline from the current price of $58.84. The analyst low target of $50 implies a 15% downside, but if the recovery fails, the stock could fall below that level, especially given the August 4 gap down from $64.31 to $50.30, which remains a resistance zone.
FAQ
The key risks include financial, operational, market, and company-specific factors. Financially, the company swung to a net loss of $52 million in Q2 2026 and has a weak FCF yield of 1.3%, with debt-to-equity of 0.83. Operationally, revenue growth has decelerated to 5.15% YoY, and operating expenses remain high at $481.3 million. Market risks include a high beta of 1.223, making the stock 22% more volatile than the S&P 500, and a short ratio of 6.29 indicating bearish sentiment. Company-specific risks include dependence on cyclical pharma and academic spending, and the potential for further margin compression if cost controls fail.
Our 12-month forecast has three scenarios: bull (25% probability, $70-$80), base (55%, $60-$68), and bear (20%, $45-$50). The base case assumes a gradual recovery with EPS meeting the consensus of $3.50 and the stock trading near the analyst average target of $63.67. The bull case requires a strong earnings beat and multiple expansion, while the bear case assumes continued losses and a retest of the $50 low. The most likely scenario is the base case, driven by modest revenue growth and margin improvement. Key catalysts include the next earnings report and any updates on cost reduction initiatives.
BRKR appears fairly valued to slightly overvalued on current earnings, but undervalued if the recovery materializes. The trailing PS of 2.08x is at the low end of its historical range (5.7x-18.7x), suggesting the market is pessimistic. However, the forward PE of 24.39x and EV/EBITDA of 29.4x are above peers, indicating a premium for expected growth. The PEG ratio of 2.62 suggests the stock is not cheap relative to its growth rate. The market is pricing in a successful earnings recovery, and any disappointment could lead to multiple compression.
BRKR is a Hold-rated stock with a balanced risk/reward profile. The analyst consensus is Buy with an average target of $63.67, implying 8.2% upside, but the company recently reported a net loss of $52 million in Q2 2026 and trades at a premium forward PE of 24.39x. The bull case relies on an earnings recovery that has not yet materialized, while the bear case points to weak cash flow and high short interest. For risk-tolerant investors with a long-term horizon, a small position could be justified, but waiting for evidence of a turnaround is prudent. A break above $66.98 or a pullback to $50 would improve the risk/reward.
BRKR is more suitable for long-term investment given its volatile earnings and the need for a turnaround to play out. The stock has a beta of 1.223 and a max drawdown of -39.85%, indicating high short-term risk. The dividend yield is only 0.32%, so income is not a primary attraction. The company's strong gross margins and installed base support a long-term thesis, but near-term earnings visibility is low. A minimum holding period of 2-3 years is recommended to allow for the cyclical recovery. Short-term trading could be opportunistic around earnings, but carries significant risk.